London pre-open: Shire boosted by FDA decision

26th Oct 2009 07:47

It is a quiet start for the week on the corporate front for London.Pharma firm Shire announced that the US Food and Drug Administration (FDA) has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate, currently marketed by Shire US for the treatment of attention-deficit hyperactivity disorder (ADHD) under the name VYVANSE.McBride, which makes personal care and household products for supermarkets to sell under their own name, said revenues in the period between 1 July and 25 October rose by 7% rise from the same period the previous year as shoppers continued looking for higher value.Galliford Try the construction and housebuilding group, has won a contract for a road improvement scheme in Scotland. The company won the £31.5m contract to construct a new 5km section of the A96 to bypass the villages of Fochabers and Mossfodloch.Bookmaker Ladbrokes said it received a 95% acceptance rate for its recent rights issue.